Natural History, Hospitalizations and Mortality Causes in ATTRv V30M Amyloidosis in an Endemic European Cohort

Why It Matters

Cardiovascular complications drive mortality and hospital use in ATTRv V30M, highlighting gaps in current care pathways and the urgency for integrated treatment strategies.

Key Takeaways

• 78% presented mixed neurological‑cardiac phenotype
• 41.8% had five+ hospital or emergency visits
• Infections, especially UTIs, topped hospitalization causes
• Cardiovascular events caused 29% of deaths

Pulse Analysis

Variant transthyretin amyloidosis (ATTRv) V30M remains a clinical challenge despite the advent of disease‑modifying agents such as tafamidis and patisiran. The Mallorca cohort, one of Europe’s most concentrated endemic foci, provides a real‑world lens on how the disease progresses when patients reach end‑stage. The study’s median survival of just under six years from diagnosis reflects the aggressive nature of the mixed cardiac‑neurologic phenotype, which is more prevalent in this population than in non‑endemic regions. Understanding these natural history metrics is essential for clinicians calibrating expectations around therapy initiation and for payers assessing long‑term value.

Hospital utilization patterns reveal that infections, particularly urinary tract infections, are the most frequent trigger for acute care encounters. This aligns with the autonomic dysfunction and gastrointestinal dysmotility common in ATTRv, which predispose patients to bacterial overgrowth and catheter‑related infections. Cardiovascular events, especially heart failure exacerbations, not only dominate admissions but also represent the leading cause of death, accounting for nearly a third of fatalities. These data suggest that while neurologic symptom management is critical, cardiology oversight must be equally prioritized to mitigate sudden death and progressive pump failure.

The implications for health systems are clear: multidisciplinary clinics that integrate neurology, cardiology, genetics, and palliative care can address the dual burden of infection risk and cardiac decline. Early identification of cardiac involvement—through biomarkers, imaging, and regular functional assessments—may enable timely escalation to advanced heart failure therapies, including device implantation or transplant evaluation. Moreover, proactive infection prevention strategies, such as routine urinary screening and catheter hygiene protocols, could reduce emergency department visits and improve quality of life. As ATTRv therapies evolve, real‑world evidence like this Mallorca study will guide resource allocation and clinical pathways, ensuring patients receive comprehensive, evidence‑based care.